Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

Jens Lundgren*, Abdel Babiker, Fred Gordin, Sean Emery, Gerd Fätkenheuer, Jean Michel Molina, Robin Wood, James D. Neaton, Brian K. Agan, Beverly Alston-Smith, Alejandro Arenas-Pinto, Jose R. Arribas, Jason V. Baker, John Baxter, Waldo H. Belloso, Kate Brekke, Bruce Brew, Susan W. Brobst, William Burman, Cate CareyRichard Clark, David A. Cooper, Richard T. Davey, Guy De La Rosa, Eileen T. Denning, Matthew Dolan, Gregory Dore, Daniel Duprez, Ezekiel Emanuel, Christine Grady, Birgit Grund, Bernard Hirschel, Bruno Hoen, Fleur Hudson, Margaret A. Johnson, Chrispin Kambili, Karin Klingman, Ken M. Kunisaki, Alan Landay, Bruno Ledergerber, Sandra N. Lehrman, Ana Martinez, Sue Meger, Kelly Misar, Ronald T. Mitsuyasu, Amanda Mocroft, David Munroe, Michael Norton, Robert C. Palmer, Sarah L. Pett, Andrew Phillips, Deenan Pillay, Danielle Porter, Richard W. Price, Michael Proschan, Claire Rappoport, Peter Reiss, Boris Renjifo, Kevin Robertson, Jürgen Rockstroh, Gabriela Rodriguez, James F. Rooney, Michael J. Ross, Mauro Schechter, Siegfried Schwarze, Daniel Seekins, Shweta Sharma, Wendy Snowden, Amalio Telenti, Jeff Tryon, Jean van Wyk, Michael J. Vjecha, Edwina Wright

*Corresponding author for this work

Research output: Contribution to journalEditorial

27 Scopus citations
Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalHIV Medicine
Volume16
Issue numberS1
DOIs
StatePublished - 1 Apr 2015

Keywords

  • Antiretroviral therapy
  • CD4-guided ART
  • HIV
  • START trial
  • When to start

Fingerprint

Dive into the research topics of 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial'. Together they form a unique fingerprint.

Cite this